Introduction
============

Gastric cancer (GC) is one of the most common cancers diagnosed, and is the third leading cause of cancer-related mortality worldwide [@B1]. Although the incidence and mortality rates of GC have steadily declined in several countries over the past few decades, these rates continue to be high in Asian countries. In particular, the Korea National Cancer Center reported that GC was the third-most common cancer in Korea in 2017, with 26,350 new cases and 7,480 deaths recorded [@B2], [@B3].

Mitochondria play a crucial role in cell energy production in the form of ATP through respiration and oxidative phosphorylation (OXPHO), generation of reactive oxygen species (ROS), and apoptosis [@B4],[@B5]. ROS are cytotoxic by-products of the mitochondria that exert damage to both genomic DNA and mitochondrial DNA (mtDNA), which results in tumorigenesis [@B6], [@B7]. Indeed, several studies have indicated that mtDNA alterations contribute to the development and progression of various types of cancer, including GC [@B8]-[@B12]. Complex I is the first step in the electron transport system of mitochondrial OXPHO, which is located within the mitochondrial inner membrane, accepts electrons from NADH, and transfers the electrons to ubiquinone. Mitochondrial NADH dehydrogenase subunit 3 (*MTND3*) is one of seven mtDNA-encoded complex I genes (*MTND1, MTND2, MTND3, MTND4, MTND5, MTND6,* and*MTND7*) [@B13]. Hung et al. [@B12] identified eight somatic mutations in mtDNA genes, including *MTND1*, *MTND2*, *MTND5*, and D-loop regions, associated with GC. In addition, Bhat et al. [@B14] reported that the single nucleotide polymorphism at locus rs2853826 in *MTND3* increased ROS production in type 2 diabetes mellitus (T2DM). To date, previous studies have shown a significant correlation of polymorphisms in *MTND3* with the risk of Parkinson\'s disease, T2DM, and breast and esophageal cancers, but not with GC [@B12], [@B14]-[@B19]. Therefore, the overall association between *MTND3* polymorphisms and GC risk remains unknown.

Accordingly, we examined whether *MTND3* polymorphisms contribute to GC risk. We first identified SNPs in *MTND3* by Sanger sequencing, and then determined their association with an increased risk of GC using a case-control study design. Further, we explored the impact of *MTND3* polymorphisms in GC on various characteristics and clinical features, including age, sex, histologic type, lymph node metastasis (LNM), T classification, and tumor stage. These findings should help to clarify population-specific markers of GC and provide insight into uncovering the tumorigenesis mechanisms toward improving the diagnosis and prognosis for patients.

Materials and methods
=====================

Subjects and DNA extraction
---------------------------

In total, 377 GC patients and 363 healthy controls were enrolled in this study. The blood samples used in this study were provided by the Chungnam National Hospital Biobank, a member of the National Biobank of Korea, which is supported and audited by the Ministry of Health and Welfare of Korea. All individuals enrolled in this study provided their written informed consent for blood collection and use. The study protocol was approved by the Institutional Review Board of the Chungnam National University Hospital. GC patients were recruited from the outpatient clinic at the Chungnam National University Hospital, and classified according to the Lauren\'s classification [@B20]. The controls subjects were randomly selected among healthy volunteers visiting the Chungnam National University Hospital medical center for their annual physical examinations, and included only individuals who had no history of cancer. Genomic DNA was extracted from the peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s instructions.

SNP identification and genotyping
---------------------------------

Polymerase chain reaction (PCR) amplification and Sanger sequencing were performed to identify SNPs and carry out genotyping. PCR primers were designed using the online Primer 3.0 software (<http://primer3.ut.ee>). The forward primer was 5′-CCACAACTCAACGGCTACAT-3′, and the reverse primer was 5′-TGGGTGTTGAGGGTTATGAG-3′. PCR products (491 bp) were sequenced using the same PCR primers and BigDye(R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosytems, Foster City, CA, USA) on an ABI PRISM 3730XL system (Applied Biosystems). The SNPs of *MTND3* were detected by sequence analysis based on the reference sequence of human MT: 10398 (GenBank accession number: NC_012920).

Statistical analysis
--------------------

Differences in age and gender between the GC and control groups were calculated by the chi-square test and independent *t*-test. Binary logistic regression was used to estimate the GC risk according to odds ratios (ORs) and 95% confidence intervals (CIs). The association analysis was adjusted by age and sex, which were included as covariates in the model. All statistical analyses were performed using the SPSS (SPSS Inc., Chicago, IL, USA), version 20.0 for Windows. *P* \< 0.05 was considered statistically significant.

Results
=======

Characteristic of the subjects and SNP identification
-----------------------------------------------------

Characteristics and clinical features of the study subjects (377 GC patients and 363 controls) are summarized in Table [1](#T1){ref-type="table"}. There was no significant difference in the age distribution between groups (*P* = 0.061), whereas the proportion of male subjects was significantly higher in the GC patients (*P* \< 0.001). Of the 377 GC patients, 201 (53.3%) were classified as intestinal type, 136 (36.1 %) as diffuse-type, and 40 (10.6%) as mixed-type. For LNM, 263 (69.8%) were in negative and 114 (30.2%) in positive. For the T classification, 224 (59.4 %), 54 (14.3 %), 9 (2.4 %), and 90 (23.9 %) were classified to T1, T2, T3, and T4, respectively. For the tumor stage, 260 (69.8 %), 37 (9.8 %), and 80 (21.2 %) were classified to stage I, II, and III, respectively. Overall, we identified five SNPs in *MTND3* in the cases and controls: rs28358278, rs2853826, rs201397417, rs41467651, and rs28358275.

Associations of SNPs and gastric cancer risk
--------------------------------------------

To determine whether the rs28358278, rs2853826, rs201397417, rs41467651, and rs28358275 variations of *MTND3* were related with the risk of GC, we compared the genotypes frequencies between the case and control groups. The genotype distributions for 5SNPs in *MTND3* were shown in Table [2](#T2){ref-type="table"}. All ORs and were 95% CIs adjusted for age and sex for allele and genotype frequencies. The rs41467651 T allele was significantly associated with GC risk (adjusted OR = 2.11, 95 % CI = 1.25-3.55, *P* = 0.005), whereas the remaining SNPs showed no significant association.

Stratified analysis for five SNPs
---------------------------------

To further evaluate the possible correlation of the five SNPs with GC risk in subgroups, we performed stratified analyses based on various characteristics including age, sex, histologic type, LNM, T classification, and tumor stage. As shown in Table [3](#T3){ref-type="table"}, the rs441467651 T allele was again found to be significantly associated with increased GC risk compared to those of controls in subjects over 60 years old (adjusted OR = 2.40, 95 % CI = 1.14-5.05, *P* = 0.021). Moreover, the rs28358278 G, rs2853826 T, and rs41467651 T allele were associated with increased GC risk compared to those of controls in female subjects (adjusted OR = 1.70, 95 % CI = 1.08-2.69, *P* = 0.023; adjusted OR = 1.78, 95 % CI = 1.11-2.85, *P* = 0.016; adjusted OR = 2.07, 95 % CI = 1.04-4.12, *P* = 0.038, respectively). A significant association was also observed between the rs441467651 T allele frequency and GC risk in subjects with diffuse-type tumors compared to that of controls (adjusted OR = 2.61, 95 % CI = 1.43-4.89, *P* = 0.002). However, the rs441467651 T allele was significantly related with increased GC risk regardless of LNM, T classification, or tumor stage compared to that of controls (adjusted OR = 2.00, 95 % CI = 1.12-3.55, *P* = 0.019 in LNM negative subjects; adjusted OR = 2.10, 95 % CI = 1.05-4.22, *P* = 0.0379 in LNM positive subjects; adjusted OR = 1.82, 95 % CI = 1.02-3.24, *P* =0.042 in T1/T2 subjects; adjusted OR = 2.60, 95 % CI = 1.29-5.24, *P* =0.007 in T3/T4 subjects; adjusted OR = 1.91, 95 % CI = 1.09-3.34, *P* =0.025 in tumor stage I (A+B)/II (A+B+C) subjects; adjusted OR = 2.36, 95 % CI = 1.12-5.13, *P* =0.025 in tumor stage III (A+B+C) subjects) compared to that of controls.

Discussion
==========

To date, several studies, including a meta-analysis, have reported that among the identified *MTND3* SNPs, rs2853826 is related to the risk of Parkinson\'s disease, T2DM, and breast and esophageal cancers, but not to GC [@B12], [@B14]-[@B19], [@B21]. In the present study, we scanned Korean-specific polymorphisms of patients with GC and healthy subjects by direct sequencing of the *MTND3* gene, and identified five SNPs: rs28358278, rs2853826, rs201397417, rs41467651, and rs28358275. However, we did not detect any Korean-specific novel SNP. The rs28358278 (Thr114Thr) and rs41467651 (Leu84Leu) SNPs are synonymous coding variants, whereas rs2853826 (Thr114Ala), rs201397417 (Ile96Thr), and rs28358275 (Ile60Thr) are non-synonymous variants. Consistent with the HapMap Asian SNP database (phase 3), no heteroplasmic SNPs were found in *MTND3* in our study population.

We investigated the possible correlation between the five SNPs and general GC risk as well as among GC subgroups. Overall, we found an association between the SNP rs41467651 and an increased risk of GC. In stratified analysis, rs28358278, rs2853826, and rs41467651 were also associated with an increased risk of GC in women, indicating an interaction of the effects of these SNPs with gender. Moreover, the rs441467651 SNP was associated with a 2.61-times increased risk of GC in patients with diffuse-type tumors than controls, representing the highest OR detected for all associations between the SNPs and the risk of GC in subgroups. Furthermore, a positive association was observed between rs41467651 and increased GC risk regardless of LNM, T classification, or tumor stage. Although the OR of rs41467651 was similar for LNM-negative and -positive patients, it was higher in the T3/T4 GC subgroup than in the T1/T2 GC subgroup. The GC risk (2.39) of harboring the rs41467651 SNP was also higher for patients in the tumor stage III (A+B+C) subgroup than for those in the tumor stage I(A+B)/ II (A+B+C) subgroup. These results demonstrated that although the rs41467651 SNP is a synonymous polymorphism, it can nevertheless contribute to the development and progression of GC.

There are some limitations of our study that should be mentioned. First, the sample size was too small to have sufficient statistical power in the stratified analysis. Second, although the role of *Helicobacter pylori* infection as a GC risk factor is controversial, we did not investigate the relevance of *MTND3* polymorphism in relation to *H. pylori* in GC owing to the unavailability of such data. Finally, we did not explore potential associations between smoking, drinking, and diet to the relationship of GC risk and polymorphisms owing to the unavailability of these data for our cohort. Thus, the effects of these factors on mediating GC risk will be assessed in future studies.

Despite these limitations, our study is the first to explore the association between *MTND3* SNPs and risk of GC and GC subgroups. Although the sample size was too small for stratified analysis, our findings suggest that the rs28358278, rs2853826, and rs41467651 SNPs in *MTND3* might increase susceptibility to developing GC. However, further detailed study of the function and mechanism are needed to clarify the impact of these SNPs in *MTND3*.
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###### 

Characteristics and clinical features in gastric cancer and control groups

  Variables                   Gastric cancers   Controls     *P*
  --------------------------- ----------------- ------------ -------------
                              (n=377)           (n=363)      
  Age (yr) (mean±SD)          60.1 ± 11.7       58.7 ± 9.1   0.061\*
  \<60                        171 (45.4)        186 (51.2)   0.122^†^
  ≥60                         206 (54.6)        177 (48.8)   
  Gender (%)                                                 
  Male                        266 (70.6)        120 (33.1)   \< 0.001^†^
  Female                      111 (29.4)        243 (66.9)   
  Histological type (%)                                      
  Intestinal                  201 (53.3)                     
  Diffuse                     136 (36.1)                     
  Mixed                       40 (10.6)                      
  T classification (%)                                       
  T1                          224 (59.4)                     
  T2                          54 (14.3)                      
  T3                          9 (2.4)                        
  T4                          90 (23.9)                      
  Lymph node metastasis (%)                                  
  Negative                    263 (69.8)                     
  Positive                    114 (30.2)                     
  Tumor stage (%)                                            
  I (A+B)                     260 (70.0)                     
  II (A+B)                    37 (9.8)                       
  III (A+B+C)                 80 (21.2)                      

SD, standard deviation.

\* Independent *t*-test.

† Two-sided chi-square test.

###### 

Genotypes/alleles frequency of DN3 polymorphisms between gastric cancers and controls as well as the association with risk of GC

  SNP           Contig position   Protein position   Genotype   GC, N (%)    CON, N (%)   OR (95% CI)^\*^    *P*
  ------------- ----------------- ------------------ ---------- ------------ ------------ ------------------ -----------
  rs28358278    10400             114                A          222 (58.9)   228 (62.8)   1.00 (ref.)        
                                                     G          155 (41.1)   135 (37.2)   1.23 (0.90-1.71)   0.190
  rs2853826     10398             114                C          244 (64.7)   248 (68.3)   1.00 (ref.)        
                                                     T          133 (35.3)   115 (31.7)   1.20 (0.86-1.67)   0.300
  rs201397417   10345             96                 A          361 (95.8)   355 (97.8)   1.00 (ref.)        
                                                     G          16 (4.2)     8 (2.2)      1.43 (0.57-3.58)   0.441
  rs41467651    10310             84                 C          325 (86.2)   335 (92.3)   1.00 (ref.)        
                                                     T          52 (13.8)    28 (7.7)     2.11 (1.25-3.55)   **0.005**
  rs28358275    10237             60                 A          363 (96.3)   350 (96.4)   1.00 (ref.)        
                                                     G          14 (3.7)     13 (3.6)     0.87 (0.38-1.98)   0.732

SNP, single nucleotide polymorphism; GC, gastric cancer; CON, controls; OR, odds ratio; CI, confidence interval; ref, reference.

\* Adjusted by age and gender.

The significant results are in bold.

###### 

Association between each SNP and clinical characteristics of gastric cancer

  Variables               GC vs. CON                                                                                                                                              
  ----------------------- ------------------ ----------- -- ------------------ ----------- -- ------------------ ------- -- ------------------ ----------- -- ------------------- -------
  Age (years)                                                                                                                                                                     
  \<60                    1.49 (0.91-2.45)   0.113          1.47 (0.88-2.44)   0.141          1.56 (0.35-6.94)   0.558      1.26 (0.57-2.83)   0.569          3.14 (0.70-14.18)   0.136
  ≥60                     0.94 (0.60-1.46)   0.775          0.91 (0.58-1.44)   0.693          1.50 (0.42-5.36)   0.536      2.40 (1.14-5.05)   **0.021**      0.40 (0.12-1.38)    0.149
  Sex                                                                                                                                                                             
  Male                    0.91 (0.59-1.42)   0.686          0.82 (0.52-1.29)   0.386          1.39 (0.44-4.40)   0.578      1.96 (0.87-4.38)   0.103          0.71 (0.25-2.02)    0.524
  Female                  1.70 (1.08-2.69)   **0.023**      1.78 (1.11-2.85)   **0.016**      1.10 (0.20-6.15)   0.915      2.07 (1.04-4.12)   **0.038**      0.91 (0.23-3.60)    0.892
  Histological type                                                                                                                                                               
  Intestinal              1.01 (0.68-1.51)   0.947          1.03 (0.69-1.55)   0.787          0.62 (0.22-1.74)   0.361      1.81 (0.95-3.47)   0.073          1.40 (0.51-3.83)    0.510
  Diffuse                 0.76 (0.50-1.15)   0.187          1.25 (0.81-1.91)   0.312          1.17 (0.29-4.64)   0.826      2.61 (1.43-4.89)   **0.002**      0.85 (0.30-2.37)    0.753
  Lymph node Metastasis                                                                                                                                                           
  Negative                1.19 (0.83-1.69)   0.346          1.18 (0.82-1.70)   0.371          1.40 (0.52-3.78)   0.505      2.00 (1.12-3.55)   **0.019**      0.94 (0.38-2.34)    0.890
  Positive                1.24 (0.49-1.94)   0.352          1.08 (0.68-1.72)   0.750          1.05 (0.25-4.31)   0.951      2.10 (1.05-4.22)   **0.037**      0.58 (0.16-0.21)    0.411
  T classification                                                                                                                                                                
  T1/T2                   1.17 (0.82-1.66)   0.384          1.15 (0.80-1.65)   0.449          1.33 (0.49-3.59)   0.573      1.82 (1.02-3.24)   **0.042**      1.04 (0.43-2.53)    0.938
  T3/T4                   1.30 (0.81-2.10)   0.274          1.14 (0.70-1.86)   0.603          1.25 (0.30-5.24)   0.757      2.60 (1.29-5.24)   **0.007**      0.44 (0.10-2.07)    0.302
  Tumor stage                                                                                                                                                                     
  I (A+B)/II (A+B+C)      1.19 (0.84-1.67)   0.332          1.18 (0.83-1.69)   0.350          1.23 (0.46-3.31)   0.682      1.91 (1.09-3.34)   **0.025**      0.90 (0.37-2.18)    0.808
  III (A+B+C)             1.26 (0.76-2.12)   0.374          1.01 (0.59-1.72)   0.985          1.64 (0.39-6.86)   0.501      2.39 (1.12-5.13)   **0.025**      0.57 (0.12-2.65)    0.472

GC, gastric cancer; CON, controls; OR, odds ratio; CI, confidence interval.

\* Adjusted by age and gender.

The significant results are in bold.
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